Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I Dose Escalation Study Using Pyrvinium Pamoate Targeting HuR in Pancreatic Ductal Adenocarcinoma

The purpose of this phase I study is to evaluate the safety and tolerability of pyrvinium pamoate in patients with pancreatic cancer.

NCT#: NCT05055323
Study ID: 20F.041
Trial Phase: Phase I

Trial Sponsor: Thomas Jefferson University
Therapies Used in This Trial: Pyrvinium Pamoate

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Back to Trial Search